Produce Phase II Clinical Data on 20 Indian Subjects to Determine Dose: CDSCO panel advises Pfizer on Ritlecitinib.

Published Date: 11 Sep 2023

New Delhi: It should be noted that the study disease is extremely heterogeneous and that no Indian subjects were included in the data from the Phase II clinical trial that was presented.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Enhanced access for patients with prostate cancer is provided by the new SPECT/CT technique, which demonstrates remarkable biomarker identification.

2.

Reducing social media to an hour a day boosts young people's self-image.

3.

Utilizing cerium/lanthanum-134 to improve cancer detection and treatment.

4.

Clinical trial: Patients with locally advanced, muscle-invasive bladder cancer do not benefit from extended lymph node removal.

5.

Can Concurrent Boost Safely Shorten Breast Cancer Radiation?


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot